Purpose: In this meta-analysis and systemic review, we focused on the effectiveness and
safety of anlotinib in patients with advanced non-small cell lung cancer (NSCLC). Methods …

Purpose Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study
aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer …

Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory
advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …

Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit
both tumor angiogenesis and signal transduction pathways associated with proliferation …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …